Taysha Gene Therapies Inc

NASDAQ:TSHAUnited States

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.

Contact Information

Headquarters

3000 Pegasus Park Drive, Suite 1430DALLAS, TX, United States 75247

Phone

214-612-0000

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Sean Nolan

President, Head of Research and Development, Director

Sukumar Nagendran

Chief Financial Officer

Kamran Alam

Director

Alison Long

Independent Director

Phillip Donenberg